Germline testing is available for add-on ordering.
Talk to a Guardant Health representative to learn more.
POST-SURGERY
Identify high-risk patients within the decision-making window for adjuvant chemotherapy.1,2
MRD, minimal residual disease.
Important note: Guardant Reveal was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.